Drug Profile
KLS 2020
Alternative Names: KLS-2020Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Kolon Life Science
- Class Analgesics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Pain in South Korea (unspecified route) (Kolon Life Science pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Pain in South Korea
- 20 Jul 2016 Preclinical trials in Pain in South Korea (unspecified route)